Compare M&T Bank Corporation (MTB) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
M&T Bank Corporation vs Novo Nordisk A/S — how do they compare? M&T Bank Corporation trades at $222.43 (market cap $31.28B), while Novo Nordisk A/S trades at $38.2 (market cap $168.73B). The key difference: Novo Nordisk A/S is far larger — about 5.4× M&T Bank Corporation's market cap, and Novo Nordisk A/S pays the higher dividend (4.7%). Which is the better fit depends on your goals — on Pluang, investors hold M&T Bank Corporation for 100 Days and Novo Nordisk A/S for 116 Days on average.
| MTB | NVO | |
|---|---|---|
Market Cap | $31.28B | $168.73B |
Volume | 934,561 | 13,531,267 |
Sector | Financials | Health |
52-Week High | $254.09 | $63.98 |
52-Week Low | $178.63 | $35.29 |
Typical Hold Time | 100 Days | 116 Days |
Enterprise Value | $47.64B | $183.05B |
Dividend Yield | 2.77% | 4.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
M&T Bank (MTB) trades at $217.56, down 0.54% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company shows solid fundamentals with a P/E of 11.47, net income margin of 30.85%, and consistent earnings beats in recent quarters. Recent news highlights dividend strength, branch expansion, and AI-driven growth initiatives.
The stock offers a compelling value proposition with a consensus price target of $258.92 (18.9% upside), supported by loan growth and efficiency gains. Key risks include interest rate sensitivity and macroeconomic pressures. Analyst sentiment is mixed, with 31% buy ratings but a majority hold stance, reflecting cautious optimism amid a challenging rate environment.
Novo Nordisk (NVO) trades at $38.18, up 1.73% with strong fundamentals including 35.35% net margin and 59.82% ROE. The stock shows mixed technical signals with bullish oscillators but bearish moving averages. Recent earnings consistently beat estimates, with Q2 2026 EPS of $0.96 surpassing the $0.82 expectation. The company maintains robust cash flow generation of $119.1B from operations in 2025.
NVO presents compelling value with a 9.71 P/E ratio and 16.8% upside to the $44.67 consensus target. Key risks include FDA regulatory delays for hemophilia drug denecimig and intensifying competition from Eli Lilly in obesity treatments. The bullish analyst consensus (59% buy ratings) supports the growth outlook despite near-term headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About M&T Bank Corporation
M&T Bank is one of the largest regional banks in the United States, with branches in New York, Pennsylvania, West Virginia, Virginia, Maryland, Delaware, and New Jersey. The bank was founded to serve manufacturing and trading businesses around the Erie Canal and is primarily focused on commercial real estate and commercial-related lending, with some retail operations also present.
Read more on MTB →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
